60 research outputs found

    Association between prostatic 18F-FDG uptake and lower urinary tract symptoms assessed by International Prostate Symptom Score

    Get PDF
    PURPOSEInflammation is known to induce prostatic growth and lower urinary tract symptoms (LUTS) progression in patients with benign prostatic hyperplasia (BPH), but clinical indicators for intraprostatic inflammation other than biopsy have not yet been established. While 2-deoxy- 2-[18F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is a useful tool for investigating inflammatory conditions, prostatic FDG uptake in patients with BPH has not been elucidated. Therefore, we evaluated the association between prostatic FDG uptake and LUTS.METHODSA total of 391 men in their 50s who underwent FDG PET/CT during health examinations were included. Mean and maximal prostatic standard uptake values (SUVs) on FDG PET/CT were measured. Prostatic volume, focal FDG uptake, and calcification were also evaluated. The International Prostate Symptom Score (IPSS) for LUTS was collected at baseline and follow- ups. The correlation between IPSS and other variables was analyzed.RESULTSThe mean age of the study participants was 51.7 years, and the mean follow-up interval was 39.7 months. The average of the mean and maximal SUV for prostatic FDG uptake was 1.8 and 2.6, respectively. The prostate volume was 18.5 cm3. The mean IPSS was 4.82 at baseline and 5.46 at follow-ups. Neither the mean SUV nor the maximal SUV of prostatic FDG uptake was correlated with IPSS at baseline or follow-ups. Conversely, prostate volume was associated with baseline IPSS and follow-up IPSS.CONCLUSIONProstatic FDG uptake did not show a significant association with IPSS on FDG PET/CT as well as at follow-ups. FDG uptake may not reflect prostatic growth in nonmalignant cases

    Elevated red cell distribution width is associated with advanced fibrosis in NAFLD

    Get PDF
    Background/AimsThe red-blood-cell distribution width (RDW) is a newly recognized risk marker in patients with cardiovascular disease, but its role in nonalcoholic fatty liver disease (NAFLD) has not been well defined. The aim of the present study was to determine the association between RDW values and the level of fibrosis in NAFLD according to BARD and FIB-4 scores.MethodsThis study included 24,547 subjects who had been diagnosed with NAFLD based on abdominal ultrasonography and questionnaires about alcohol consumption. The degree of liver fibrosis was determined according to BARD and FIB-4 scores. The association between RDW values and the degree of fibrosis in NAFLD was analyzed retrospectively.ResultsAfter adjusting for age, hemoglobin level, mean corpuscular volume, history of hypertension, history of diabetes, and high-sensitivity C-reactive protein, the RDW values were 12.61Β±0.41% (meanΒ±SD), 12.70Β±0.70%, 12.77Β±0.62%, 12.87Β±0.82%, and 13.25Β±0.90% for those with BARD scores of 0, 1, 2, 3, and 4, respectively, and 12.71Β±0.72%, 12.79Β±0.66%, and 13.23Β±1.52% for those with FIB-4 scores of <1.30, 1.31-2.66, and β‰₯2.67, respectively (P<0.05). The prevalence of advanced fibrosis (BARD score of 24 and FIB-4 score of β‰₯1.3) increased with the RDW [BARD score: 51.1% in quartile 1 (Q1) vs. 63.6% in Q4; FIB-4 score: 6.9% in Q1 vs. 10.5% in Q4; P<0.001]. After adjustments, the odds ratio of having advanced fibrosis for those in Q4 compared to Q1 were 1.76 (95%CI=1.55-2.00, P<0.001) relative to BARD score and 1.69 (95%CI=1.52-1.98, P<0.001) relative to FIB-4 score.ConclusionsElevated RDW is independently associated with advanced fibrosis in NAFLD

    Clinical Effectiveness of Urinary Human Chorionic Gonadotropin Related Protein (hCGRP) Quantification for Diagnosis of Ectopic Pregnancy

    Get PDF
    We detected pregnancy related new molecule, human chorionic gonadotropin related protein (hCGRP) in the urine of a pregnant women by using a monoclonal antibody against the human chorionic gonadotropin (hCG). This study examined the effectiveness of urinary hCGRP quantification in diagnosing ectopic pregnancy. This study included 40 normal pregnant women and 25 patients with ectopic pregnancy. Patients' serum and urinary intact whole hCG (i-hCG) and hCGRP concentrations were measured using sandwich ELISA and the ratio of hCGRP to i-hCG was calculated. Statistical analysis was performed using statistical package for social sciences (SPSS) 10.0. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the cut-off value to discriminate ectopic pregnancies from normal intrauterine pregnancies. Urinary hCGRP and hCGRP/i-hCG ratio in ectopic pregnancy group (14Β±6.6 ng/mL, 4.6Β±1.9%, respectively) were significantly lower than those of normal pregnancy group (149Β±10.2 ng/mL, 29.7Β±1.9%, respectively; p<0.001). Based on ROC curve analysis, a cut-off point of urinary hCGRP/i-hCG ratio <16.2% discriminated between ectopic pregnancy and normal pregnancy with a sensitivity, specificity, positive predictive value and negative predictive value of 92.0%, 90.0%, 32.6%, and 99.5%, respectively. Urinary hCGRP/i-hCG ratio measurement may be effective in diagnosing ectopic pregnancy

    Effect of aging on expression of nitric oxide and inducible nitric oxide synthase in human gingival fibroblasts

    No full text
    μΉ˜μ£Όμ§ˆν™˜μ˜ 진행이 λ‚˜μ΄μ— μ˜ν•΄ 영ν–₯을 λ°›λŠ”λ‹€λŠ” 사싀은 μ•Œλ €μ Έ μžˆμœΌλ‚˜ 노화에 λ”°λ₯Έ 치주쑰직 μ„Έν¬μ˜ κΈ°λŠ₯적인 변화에 κ΄€ν•œ 사싀은 많이 μ•Œλ €μ Έ μžˆμ§€ μ•Šλ‹€. 노화에 λ”°λ₯Έ μ„Έν¬μ˜ λ…Έν™”κ°€ μΉ˜μ£Όμ§ˆν™˜μ˜ 진행에 μ–΄λ– ν•œ μ—¬ν–₯을 λΌμΉ˜λŠ”κ°€λ₯Ό μ•„λŠ” 것은 μ€‘μš”ν•˜λ‹€. 염증 μƒνƒœμ—μ„œ nitric oxide (NO)λŠ” 쑰직 νŒŒκ΄΄μ— κ΄€μ—¬ν•˜λŠ” 인자둜 μž‘μš©ν•˜μ—¬ μΉ˜μ£Όμ§ˆν™˜μ˜ 진행에 κ΄€μ—¬ν•˜λŠ” κ²ƒμœΌλ‘œ μ•Œλ €μ Έ μžˆλ‹€. λ”°λΌμ„œ 이 μ—°κ΅¬λŠ” μ‚¬λžŒμ˜ μΉ˜μ€μ—μ„œ λ°°μ–‘λœ μΉ˜μ€μ„¬μœ μ•„μ„Έν¬λ₯Ό μ΄μš©ν•˜μ—¬ μ„Έν¬μ˜ 노화에 λ”°λ₯Έ NO와 이의 ν•©μ„±νš¨μ†ŒμΈ inducible nitric oxide synthase (iNOS)의 λ°œν˜„μ„ μ•Œμ•„λ΄„μœΌλ‘œμ¨ μ„Έν¬μ˜ λ…Έν™”κ°€ μΉ˜μ£Όμ§ˆν™˜μ˜ 진행에 λΌμΉ˜λŠ” 영ν–₯에 λŒ€ν•΄ μ•Œμ•„λ³΄κ³ μž ν•˜μ˜€λ‹€. 10μ„Έμ˜ ν™˜μžμ™€ 55μ„Έμ˜ ν™˜μžμ—μ„œ 각각 μ±„μ·¨ν•œ μΉ˜μ€μ—μ„œ λ°°μ–‘λœ 세포와 10μ„Έμ˜ ν™˜μžμ—μ„œ μ±„μ·¨ν•œ 세포λ₯Ό 계속적인 κ³„λŒ€λ°°μ–‘μ„ 톡해 얻은 μ‹€ν—˜μ‹€ 상 λ…Έν™”λœ 세포λ₯Ό ν¬ν•¨ν•˜μ—¬ 총 3 μ’…λ₯˜μ˜ μΉ˜μ€μ„¬μœ μ„Έν¬λ₯Ό μ‹€ν—˜μ— μ΄μš©ν•˜μ˜€λ‹€. Hot phenol-water extraction을 톡해 μΆ”μΆœλœ Porphyromonas, gingivalis ATCC 33277 lipopolysaccharide (LPS)와 μž¬μ‘°ν•© λ₯Ό 세포에 μ μš©μ‹œμΌœ Griess assayλ₯Ό 톡해 μ‘°κ±΄ν™”λœ λ°°μ§€μ—μ„œ NOλ₯Ό μΈ‘μ •ν•˜μ˜€λ‹€. 20세와 55μ„Έμ˜ ν™˜μžμ—μ„œ μ±„μ·¨λœ μΉ˜μ€ 쑰직과 총 3 μ’…λ₯˜μ˜ λ°°μ–‘λœ 세포에 NOS-II 항체λ₯Ό μ μš©μ‹œμΌœ iNOS λ‹¨λ°±μ§ˆ λ°œν˜„μ„ κ΄€μ°°ν•˜μ˜€λ‹€. Total RNAλ₯Ό μΆ”μΆœν•˜μ—¬ RT-PCRλ₯Ό 톡해 iNOS mRNA의 λ°œν˜„μ„ λΆ„μ„ν•˜μ˜€λ‹€. μΉ˜μ€μ„¬μœ μ•„μ„Έν¬μ—μ„œ NOλŠ” 자발적으둜 λ°œμƒλ˜μ—ˆκ³ , μ΄λŸ¬ν•œ λ°œν˜„μ€ μ Šμ€ 세포보닀 λ…Έν™”λœ μ„Έν¬μ—μ„œ κ°•ν•˜μ˜€λ‹€. P, gingivalis LPS와 μ œμ‘°ν•© λŠ” μΉ˜μ€μ„¬μœ μ•„μ„Έν¬μ—μ„œ NO의 λ°œν˜„μ„ μ¦κ°€μ‹œμΌ°κ³ , μ΄λŸ¬ν•œ λ°œν˜„μ€ μ Šμ€ 세포보닀 λ…Έν™”λœ μ„Έν¬μ—μ„œ κ°•ν•˜μ˜€λ‹€. 면역쑰직화학 μ—Όμƒ‰μ—μ„œ iNOS λ‹¨λ°±μ§ˆμ€ μ Šμ€ μ‚¬λžŒκ³Ό λ…Έν™”λœ μ‚¬λžŒμ˜ μΉ˜μ€ 쑰직 λͺ¨λ‘μ—μ„œ μΉ˜μ€μ„¬μœ μ•„μ„Έν¬μ™€ μƒν”Όμ˜ κΈ°μ €μΈ΅ 세포와 μ—Όμ¦μ„Έν¬μ—μ„œ λ°œν˜„λ˜μ—ˆμœΌλ‚˜ 노화에 λ”°λ₯Έ λ°œν˜„μ˜ 차이λ₯Ό ꡬ별할 μˆ˜λŠ” μ—†μ—ˆλ‹€. μ„Έν¬μ˜ λ©΄μ—­μ—Όμƒ‰μ—μ„œ iNOS λ‹¨λ°±μ§ˆμ€ λ…Έν™”λœ μ„Έν¬μ—μ„œ κ°•ν•˜κ²Œ λ°œν˜„λ˜μ—ˆκ³  μ΄λŸ¬ν•œ λ°œν˜„μ€ LPS와 에 μ˜ν•΄ κ°•ν™”λ˜μ—ˆλ‹€. LPS와 의 쑰건이 주어지지 μ•Šμ€ μƒνƒœμ—μ„œ iNOS mRNAλŠ” μ Šμ€ μ„Έν¬μ—μ„œλ³΄λ‹€ λ…Έν™”λœ μ„Έν¬μ—μ„œ κ°•ν•˜κ²Œ λ°œν˜„λ˜μ—ˆλ‹€. μ΄λŸ¬ν•œ κ²°κ³Όλ₯Ό 톡해 μ„Έν¬μ˜ λ…Έν™”κ°€ NO와 iNOS λ°œν˜„μ„ μ¦κ°€μ‹œν‚΄μœΌλ‘œμ„œ μΉ˜μ£Όμ§ˆν™˜μ˜ 진행에 영ν–₯을 끼칠 수 μžˆμŒμ„ μ‹œμ‚¬ν•˜μ˜€λ‹€.This study was supported by a grant of the Korea Health 21 R&D project, Ministy of Health & Welfare, Republix of Korea(03-PJ1-CH08-001)

    λ…Έν™”κ°€ μ‚¬λžŒ μΉ˜μ€μ„¬μœ μ•„μ„Έν¬μ˜ nitric oxide와 inducible nitric oxide synthase λ°œν˜„μ— λΌμΉ˜λŠ” 영ν–₯

    No full text
    μΉ˜μ£Όμ§ˆν™˜μ˜ 진행이 λ‚˜μ΄μ— μ˜ν•΄ 영ν–₯을 λ°›λŠ”λ‹€λŠ” 사싀은 μ•Œλ €μ Έ μžˆμœΌλ‚˜ 노화에 λ”°λ₯Έ 치주쑰직 μ„Έν¬μ˜ κΈ°λŠ₯적인 변화에 κ΄€ν•œ 사싀은 많이 μ•Œλ €μ Έ μžˆμ§€ μ•Šλ‹€. 노화에 λ”°λ₯Έ μ„Έν¬μ˜ λ…Έν™”κ°€ μΉ˜μ£Όμ§ˆν™˜μ˜ 진행에 μ–΄λ– ν•œ μ—¬ν–₯을 λΌμΉ˜λŠ”κ°€λ₯Ό μ•„λŠ” 것은 μ€‘μš”ν•˜λ‹€. 염증 μƒνƒœμ—μ„œ nitric oxide (NO)λŠ” 쑰직 νŒŒκ΄΄μ— κ΄€μ—¬ν•˜λŠ” 인자둜 μž‘μš©ν•˜μ—¬ μΉ˜μ£Όμ§ˆν™˜μ˜ 진행에 κ΄€μ—¬ν•˜λŠ” κ²ƒμœΌλ‘œ μ•Œλ €μ Έ μžˆλ‹€. λ”°λΌμ„œ 이 μ—°κ΅¬λŠ” μ‚¬λžŒμ˜ μΉ˜μ€μ—μ„œ λ°°μ–‘λœ μΉ˜μ€μ„¬μœ μ•„μ„Έν¬λ₯Ό μ΄μš©ν•˜μ—¬ μ„Έν¬μ˜ 노화에 λ”°λ₯Έ NO와 이의 ν•©μ„±νš¨μ†ŒμΈ inducible nitric oxide synthase (iNOS)의 λ°œν˜„μ„ μ•Œμ•„λ΄„μœΌλ‘œμ¨ μ„Έν¬μ˜ λ…Έν™”κ°€ μΉ˜μ£Όμ§ˆν™˜μ˜ 진행에 λΌμΉ˜λŠ” 영ν–₯에 λŒ€ν•΄ μ•Œμ•„λ³΄κ³ μž ν•˜μ˜€λ‹€. 10μ„Έμ˜ ν™˜μžμ™€ 55μ„Έμ˜ ν™˜μžμ—μ„œ 각각 μ±„μ·¨ν•œ μΉ˜μ€μ—μ„œ λ°°μ–‘λœ 세포와 10μ„Έμ˜ ν™˜μžμ—μ„œ μ±„μ·¨ν•œ 세포λ₯Ό 계속적인 κ³„λŒ€λ°°μ–‘μ„ 톡해 얻은 μ‹€ν—˜μ‹€ 상 λ…Έν™”λœ 세포λ₯Ό ν¬ν•¨ν•˜μ—¬ 총 3 μ’…λ₯˜μ˜ μΉ˜μ€μ„¬μœ μ„Έν¬λ₯Ό μ‹€ν—˜μ— μ΄μš©ν•˜μ˜€λ‹€. Hot phenol-water extraction을 톡해 μΆ”μΆœλœ Porphyromonas, gingivalis ATCC 33277 lipopolysaccharide (LPS)와 μž¬μ‘°ν•© IFN-Ξ³λ₯Ό 세포에 μ μš©μ‹œμΌœ Griess assayλ₯Ό 톡해 μ‘°κ±΄ν™”λœ λ°°μ§€μ—μ„œ NOλ₯Ό μΈ‘μ •ν•˜μ˜€λ‹€. 20세와 55μ„Έμ˜ ν™˜μžμ—μ„œ μ±„μ·¨λœ μΉ˜μ€ 쑰직과 총 3 μ’…λ₯˜μ˜ λ°°μ–‘λœ 세포에 NOS-II 항체λ₯Ό μ μš©μ‹œμΌœ iNOS λ‹¨λ°±μ§ˆ λ°œν˜„μ„ κ΄€μ°°ν•˜μ˜€λ‹€. Total RNAλ₯Ό μΆ”μΆœν•˜μ—¬ RT-PCRλ₯Ό 톡해 iNOS mRNA의 λ°œν˜„μ„ λΆ„μ„ν•˜μ˜€λ‹€. μΉ˜μ€μ„¬μœ μ•„μ„Έν¬μ—μ„œ NOλŠ” 자발적으둜 λ°œμƒλ˜μ—ˆκ³ , μ΄λŸ¬ν•œ λ°œν˜„μ€ μ Šμ€ 세포보닀 λ…Έν™”λœ μ„Έν¬μ—μ„œ κ°•ν•˜μ˜€λ‹€. P, gingivalis LPS와 μ œμ‘°ν•© IFN-Ξ³λŠ” μΉ˜μ€μ„¬μœ μ•„μ„Έν¬μ—μ„œ NO의 λ°œν˜„μ„ μ¦κ°€μ‹œμΌ°κ³ , μ΄λŸ¬ν•œ λ°œν˜„μ€ μ Šμ€ 세포보닀 λ…Έν™”λœ μ„Έν¬μ—μ„œ κ°•ν•˜μ˜€λ‹€. 면역쑰직화학 μ—Όμƒ‰μ—μ„œ iNOS λ‹¨λ°±μ§ˆμ€ μ Šμ€ μ‚¬λžŒκ³Ό λ…Έν™”λœ μ‚¬λžŒμ˜ μΉ˜μ€ 쑰직 λͺ¨λ‘μ—μ„œ μΉ˜μ€μ„¬μœ μ•„μ„Έν¬μ™€ μƒν”Όμ˜ κΈ°μ €μΈ΅ 세포와 μ—Όμ¦μ„Έν¬μ—μ„œ λ°œν˜„λ˜μ—ˆμœΌλ‚˜ 노화에 λ”°λ₯Έ λ°œν˜„μ˜ 차이λ₯Ό ꡬ별할 μˆ˜λŠ” μ—†μ—ˆλ‹€. μ„Έν¬μ˜ λ©΄μ—­μ—Όμƒ‰μ—μ„œ iNOS λ‹¨λ°±μ§ˆμ€ λ…Έν™”λœ μ„Έν¬μ—μ„œ κ°•ν•˜κ²Œ λ°œν˜„λ˜μ—ˆκ³  μ΄λŸ¬ν•œ λ°œν˜„μ€ LPS와 IFN-γ에 μ˜ν•΄ κ°•ν™”λ˜μ—ˆλ‹€. LPS와 IFN-γ의 쑰건이 주어지지 μ•Šμ€ μƒνƒœμ—μ„œ iNOS mRNAλŠ” μ Šμ€ μ„Έν¬μ—μ„œλ³΄λ‹€ λ…Έν™”λœ μ„Έν¬μ—μ„œ κ°•ν•˜κ²Œ λ°œν˜„λ˜μ—ˆλ‹€. μ΄λŸ¬ν•œ κ²°κ³Όλ₯Ό 톡해 μ„Έν¬μ˜ λ…Έν™”κ°€ NO와 iNOS λ°œν˜„μ„ μ¦κ°€μ‹œν‚΄μœΌλ‘œμ„œ μΉ˜μ£Όμ§ˆν™˜μ˜ 진행에 영ν–₯을 끼칠 수 μžˆμŒμ„ μ‹œμ‚¬ν•˜μ˜€λ‹€.This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea(03-PJ1-PG1-CH08-0001)

    μΈκ°„μ˜ λ°œμΉ˜μ™€ λ‚΄μ—μ„œ κ³¨μœ λ„μž¬μƒμˆ  ν›„μ˜ μΉ˜μœ μ–‘μƒ

    No full text
    이 μ—°κ΅¬λŠ” μž„ν”Œλž€νŠΈλ₯Ό μ‹λ¦½ν•˜κΈ°λ₯Ό μ›ν•˜λŠ” μ „μ‹ κ±΄κ°•μƒνƒœκ°€ μ–‘ν˜Έν•˜λ©° κ΅¬κ°•μœ„μƒμƒνƒœκ°€ 쒋은 14λͺ… ν™˜μž(λ‚¨μž:8λͺ…, μ—¬μž:6λͺ…, ν‰κ· λ‚˜μ΄ : 44μ„Έ)의 20개의 λ°œμΉ˜μ™€ 내에 ν‘μˆ˜μ„± 차폐막(BioMesh. Sam Yang Corporation, Korea)κ³Ό ν•¨κ»˜ νƒˆνšŒλƒ‰λ™ 건쑰동쒅 골(dem-ineralized freezedried bone allografts, 250-500γŽ›. Pacific Coast Tissue Bank, U.S.A.)κ³Ό 이쒅골(Bovine-Bone, Bio-Oss 0.25-1.0 mm, Geistlich, Biomaterials and Osteohealth, Switzerland)을 1:1(λΆ€ν”Ό)둜 ν˜Όν•©ν•˜μ—¬ μ΄μ‹ν•œ ν›„ κ·Έ μΉ˜μœ μ–‘μƒμ„ κ΄€μ°°ν•˜κ³ μž 쑰직학적 및 λ©΄μ—­μ‘°μ§ν™”ν•™μ μœΌλ‘œ ν‰κ°€ν•˜μ˜€λ‹€. μ΄μ§μž¬κ°€ νƒˆλ½λ˜λŠ” 것을 λ°©μ§€ν•˜κΈ° μœ„ν•˜μ—¬ λ°œμΉ˜ν•œ ν›„ 1개윌이 경과된 후에 μ΄μ‹μž¬μ™€ 차폐막을 μœ„μΉ˜μ‹œμΌ°λ‹€. ν‘œλ³Έμ œμž‘μ„ μœ„ν•˜μ—¬ μ΄μ‹μˆ μ„ μ‹œν–‰ν•œ 지 μ•½ 6개윌 후에 μž„ν”Œλž€νŠΈλ₯Ό μ‹λ¦½ν•˜κΈ° 직전 μ‹λ¦½λΆ€μœ„μ—μ„œ trephine bur둜 골을 μ±„μ·¨ν•˜μ˜€λŠ”λ°, 20증둀 쀑 7μ¦λ‘€μ—μ„œ μž„ν”Œλž€νŠΈλ₯Ό μ‹λ¦½ν•˜κΈ° 전에 차폐막이 λ…ΈμΆœλ˜μ—ˆλ‹€. 차폐막이 λ…ΈμΆœλ˜μ§€ μ•Šμ€ 것을 λŒ€μ‘°κ΅°μœΌλ‘œ, λ…ΈμΆœλœ 것을 μ‹€ν—˜κ΅°μœΌλ‘œ μ„€μ •ν•˜μ˜€λ‹€. 쑰직학적인 관찰을 μœ„ν•˜μ—¬ 톡상적인 방법에 따라 νƒˆνšŒ ν‘œλ³Έμ„ μ œμž‘ν•˜μ˜€κ³ , alkaline phosphotase(ALP)ν‹€ μ΄μš©ν•˜μ—¬ 면역쑰직화학적 염색을 μ‹œν–‰ν•œ ν›„ 골 ν˜•μ„± μƒνƒœλ₯Ό ν‰κ°€ν•˜μ—¬ λ‹€μŒκ³Ό 같은 κ²°κ³Όλ₯Ό μ–»μ—ˆλ‹€. λ³Έ μ—°κ΅¬μ—μ„œλŠ” λ°œμΉ˜μ™€λ‚΄μ—μ„œ κ³¨μœ λ„μž¬μƒμˆ  ν›„ λ‚˜νƒ€λ‚˜λŠ” 치유 ν˜•νƒœλ₯Ό 5가지 ν˜•νƒœλ‘œ λΆ„λ₯˜ν•  수 μžˆμ—ˆλ‹€. Type I, II와 IIIλŠ” μƒˆλ‘œμš΄ 골 ν˜•μ„±μ„ λ‚˜νƒ€λ‚΄μ§€ μ•Šμ•˜κ³ , 면역쑰직화학적 검사 μ‹œ ALP μŒμ„± μ†Œκ²¬μ„ λ‚˜νƒ€λ‚΄μ—ˆλ‹€. Type VλŠ” μƒˆλ‘œμš΄ 골 ν˜•μ„±κ³Ό ALP μ–‘μ„± μ†Œκ²¬μ„ λ‚˜νƒ€λ‚΄μ—ˆμœΌλ‚˜ 염증, 괴사, κ²°ν•©μ‘°μ§μ˜ 증식 등은 μ—†μ—ˆλ‹€. Type IV와 Type V의 μ°¨μ΄λŠ” κ²°ν•©μ‘°μ§μ˜ μ¦μ‹μ—¬λΆ€λ‘œ κ΅¬λΆ„λ˜μ—ˆλ‹€. 막이 λ…ΈμΆœλ˜μ§€μ•Šμ€ 증둀듀 쀑 7 μ¦λ‘€μ—μ„œλŠ” Type V의 치유 ν˜•νƒœλ₯Ό, 2μ¦λ‘€μ—μ„œλŠ” Type IV의 치유 ν˜•νƒœλ₯Ό λ‚˜νƒ€λ‚΄μ—ˆλ‹€. 막이 λ…ΈμΆœλ˜μ—ˆλ˜ μ¦λ‘€μ—μ„œλŠ” Type I, II, III의 λ‹€μ–‘ν•œ 치유 ν˜•νƒœλ₯Ό λ‚˜νƒ€λ‚΄μ—ˆλ‹€. λ³Έ 연ꡬ결과, λ°œμΉ˜μ™€ 내에 κ³¨μœ λ„μž¬μƒμˆ μ„ μ‹œν–‰ν•œ ν›„ μ°¨νλ§‰μ˜ λ…ΈμΆœ μ—¬λΆ€κ°€ 신생골 ν˜•μ„±μ— μ€‘μš”ν•œ 영ν–₯을 λ―ΈμΉ  κ²ƒμœΌλ‘œ μ‚¬λ£Œλ˜λ©°, λ³Έ μ—°κ΅¬μ—μ„œ λΆ„λ₯˜ν•œ 치유 ν˜•νƒœκ°€ ν–₯ν›„ κ³¨μœ λ„μž¬μƒμˆ  ν›„μ˜ κ²°κ³Ό 뢄석에 ν™œμš©λ  수 μžˆμ„ κ²ƒμœΌλ‘œ μ‚¬λ£Œλœλ‹€.This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare. Republic of Korea(03-PJ1-PG1-CH08-0001)
    • …
    corecore